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A Dual AP-1 and SMAD Decoy ODN Suppresses
Tissue Fibrosis and Scarring in Mice
Hong-Feng Yuan1,2,6, Hong Huang1,6, Xiang-Yun Li1, Wei Guo1, Wei Xing1, Zhi-Ya Sun3, Hua-Ping Liang1,
Jian Yu4, Dong-Feng Chen3, Zheng-Guo Wang1, Jin Hao5 and Xiang Xu1,3
The transforming growth factor-b (TGF-b) signaling pathway promotes tissue fibrosis and scarring through SMAD
(small mothers against decapentaplegic)-dependent and SMAD-independent mechanisms. However, inhibition
of SMAD-mediated signal transduction alone induces an excessive inflammatory response that impairs the
antifibrotic effects of TGF-b inhibitors. In this study, we designed and characterized a dual-functional
transcription activator protein 1 (AP-1) and SMAD decoy oligodeoxynucleotide, antifibrosis oligodeoxynucleotide
4 (AFODN4) in vitro and in vivo. AFODN4 binds directly to recombinant AP-1 and SMAD with high affinity.
AFODN4 significantly inhibited the DNA-binding and transcriptional activities of both AP-1 and SMAD, as well
as the production of fibrotic mediators stimulated by TGF-b1 or TGF-b2 in L929 murine fibroblasts. Local
administration of AFODN4 significantly inhibited fibrosis associated with acute dermal wounds in mice.
Intriguingly, AFODN4 inhibited AP-1-mediated production of proinflammatory mediators, which can be caused
by blockage of SMAD alone in vitro and in vivo. Collectively, these findings suggest that dual inhibition of SMAD
and AP-1 signaling by AFODN4 is a useful strategy for the development of new antifibrotic agents.
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INTRODUCTION
Tissue repair is a complex biological process involving the
regeneration of both the cellular and extracellular matrix
components, and is regulated by the coordinated interactions
of multiple cytokines (Martin, 1997). Over the course of
normal tissue repair, a balanced cytokine network composed
of positive and negative feedback loops is responsible for the
proper activation and termination of the proliferative and
fibrotic processes. Deregulation in these feedback mecha-
nisms can lead to continuous extracellular matrix secretion
and deposition, as well as tissue fibrosis or hypertrophic scars.
Multiple lines of evidence suggest that the transforming
growth factor-b (TGF-b) pathway is a central signaling
pathway in the development of tissue fibrosis and scarring
(Eickelberg, 2001; Pohlers et al., 2009).
The TGF-b super family regulates many cellular functions
including cell growth, differentiation, adhesion, migration,
and apoptosis (Ikushima and Miyazono, 2011). Abnormal
TGF-b signaling has been implicated in a growing number
of fibrotic and inflammatory conditions, including pulmonary
fibrosis, liver cirrhosis, systemic sclerosis, and hypertrophic
scars (Schiller et al., 2004; Gordon and Blobe, 2008; Varga
and Pasche, 2008; Pohlers et al., 2009). Targeting TGF-b
signaling might therefore bring potential new therapies for the
treatment of fibrotic and inflammatory diseases.
TGF-bs propagate their signals through two major pathways.
The canonical pathway is activated upon binding of TGF-b
ligands to their receptors, TbRs, leading to the phosphorylation
of downstream effectors SMAD2/3 and their heterodimeriza-
tion with SMAD4. SMAD (small mothers against decapenta-
plegic) heterodimers translocate into the nucleus, where they
regulate the transcription of target genes via SMAD-binding
elements with a consensus sequence of 50-CAGA-30
(Eickelberg, 2001; Piek et al., 2001). In noncanonical path-
ways, TGF-bs signal through mitogen-activated protein kinase
and transcription activator protein 1 (AP-1) independently of
SMAD phosphorylation or activation. Accumulating evidence
suggests that the AP-1 pathway plays a key role in the
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transcription of many genes related to fibrogenesis, such as
plasminogen activator inhibitor-1 (PAI-1), TGF-b1, fibronectin,
and type I collagen, via 12-O-tetradecanoylphorbol-13-
acetate–response elements with a consensus sequence of
50-TGACTCA-30 in their promoters (Hocevar et al., 1999;
Eickelberg, 2001; Vulin and Stanley, 2004; Kook et al.,
2011). In addition, SMAD can enhance the transcription of
c-fos, a subunit of the AP-1 complex (Piek et al., 2001). The
binding of SMAD and AP-1 to their corresponding cis
elements is a key step in TGF-b signal transduction.
However, the specific contribution of each pathway and
how their cross-talk ultimately determines the outcome of
TGF-b-initiated cellular response are not well defined
(Eickelberg, 2001; Piek et al., 2001).
Most inhibitors of the TGF-b pathway developed to date
either inhibit the binding between the ligands and receptors or
block the kinase activity of TGF-b family receptors. Unfortu-
nately, these compounds have yielded little success in clinical
practice (Varga and Pasche, 2008; Bonafoux and Lee, 2009;
Santibanez et al., 2011). In addition, blockage of SMAD-
dependent signaling induces excessive inflammation, which
impairs the antifibrotic effects of TGF-b inhibitors (Walia et al.,
2003; Anthoni et al., 2008; Sivakumar and Das, 2008).
Another approach to inhibit TGF-b signaling is to interfere
with the binding of transcription factors such as SMAD or AP-
1 to the promoter of target genes, which appears amenable to
the design of more specific inhibitors. However, only a limited
number of agents have been developed on the basis of this
approach. In this study, we report the design and
characterization of a dual-functional decoy oligodeoxy-
nucleotide designated antifibrosis oligodeoxynucleotide
4 (AFODN4). AFODN4 significantly suppressed tissue
fibrosis without a concomitant increase of an inflammatory
response by simultaneous sequestration of SMAD and AP-1
from TGF-b signaling.
RESULTS
Identification of dual-functional AP-1 and SMAD decoy ODNs
Abnormal TGF-b signaling via both SMAD and AP-1 is
implicated in fibrotic and inflammatory conditions (Gordon
and Blobe, 2008; Varga and Pasche, 2008; Pohlers et al.,
2009). To target both of these arms, we first designed four
decoy ODNs based on AP-1- and SMAD-binding sites
(Supplementary Table S1 online). Using surface plasmon
resonance, we found that all four AFODNs displayed high-
affinity interactions with human recombinant c-jun and
SMAD3, although AFODN4 displayed the highest affinity
(Figure 1a and Table 1). As expected, AP-1 decoy, SMAD
decoy, or scramble double-stranded ODN (dsODN) could
bind to c-jun, SMAD3, or neither. Using supershift electro-
phoretic mobility shift assays, we showed that AP-1 decoy,
SMAD decoy dsODN, or cold probes, but not scramble
dsODN, significantly blocked the binding of AP-1(c-fos/c-
jun) or SMAD3/4 to their probes. Similarly, AFODN4 inhibited
800
AP-1 dsODN
Smad dsODN AFODN1
Scramble dsODN
Scramble dsODNAFODN2
Scramble dsODN
Scramble dsODNAFODN3
AFODN4
Scramble dsODN
Scramble dsODN
21
600
600
400
400
300
400
500
200
200
200
100
–100
0
0 2 4 6
Time (minutes)
8 10 12 14 16
0 2 4 6
1 2
Time (minutes)
AFODN4 (μM) –
–
–
–
–
+
+
–
–
–
–
+
+
+
1
–
–
–
+
+
+
10
–
–
–
+
+
+
100
–
–
–
+
+
+
–
100
–
–
+
+
+
–
–
100
–
+
+
+
–
–
–
100
+
+
+
–
–
–
–
–
+
+
–
–
–
–
+
+
+
1
–
–
–
+
+
+
10
–
–
–
+
+
+
100
–
–
–
+
+
+
–
100
–
–
+
+
+
–
–
100
–
+
+
+
–
–
–
–
+
+
+
AFODN4 (μM)
AP-1 dsODN (μM)
Scramble dsODN (μM) Scramble dsODN (μM)
Smad dsODN (μM)
Nuclear extracts (5 μg) Nuclear extracts (5 μg)
32P lableled probe (1 μM) 32P lableled probe (1 μM)
Cold probe (μM) Cold probe (μM)
Anti-c-fos antibody (2.5 μL)
Supershift
Shift
Supershift
Shift
Anti-Smad4 antibody (2.5 μL)
8 10 12 14 16 0 2
1 2
4 6
Time (minutes)
8 10 12 14 16 0 2 4 6
Time (minutes)
8 10 12 14 16
0 2 4 6
Time (minutes)
2 211
8 10 12 14 16 0 2 4 6
Time (minutes)
8 10 12 14 16
R
es
po
ns
e 
a
rc
 s
e
co
n
ds
)
R
es
po
ns
e
(ar
c s
ec
on
ds
)
R
es
po
ns
e
(ar
c s
ec
on
ds
)
R
es
po
ns
e
(ar
c s
ec
on
ds
)
R
es
po
ns
e
(ar
c s
ec
on
ds
)
R
es
po
ns
e
(ar
c s
ec
on
ds
)
0
0
–200
–200
–200
300
400
200
100
–100
0
–200
300
400
500
200
100
–100
0
–200
300
400
500
600
200
100 1 2
–100
0
–200
Figure 1. The binding of dual-functional decoy double-stranded oligodeoxynucleotides (dsODNs) with transcription activator protein 1 (AP-1) and SMAD (small
mothers against decapentaplegic). (a) Interaction of the indicated dsODNs with c-jun or SMAD3 analyzed using surface plasmon resonance. Recombinant c-jun
and SMAD3 (1.25mg) were injected at the experimental times 1 and 2, respectively. (b) The DNA-binding activity of AP-1 (left) or SMAD (right) with or without
antifibrosis ODN4 (AFODN4) was analyzed by supershift electrophoretic mobility shift assay (EMSA) using nuclear extracts from NIH3T3 cells treated with
5 ng ml 1 of transforming growth factor-b (TGF-b1).
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the DNA-binding activities of both AP-1 and SMAD in a dose-
dependent manner (Figure 1b).
Using reporter assays, we found that AFODN4 was the most
potent among four AFODNs to inhibit the transcriptional
activities of AP-1 and SMAD in response to TGF-b1/TGF-b2,
by 70–80% (AFODN4 vs. Control, for AP-1: 7.2±0.9/
6.8±0.7 vs. 25.8±1.9/26.2±2.1; for SMAD: 8.8±1.6/
9.8±1.3 vs. 48.8±4.8/44.2±4.6; Figure 2a and b). AFODN4
inhibited the transcriptional activities of both AP-1 and SMAD
in a dose-dependent manner (Figure 2c). However, AFODN4
did not inhibit the activity of NF-kB or signal transducer and
activator of transcription (STAT)-1/3 (Figure 2d and e). The
highest potency of AFODN4 might be explained by the
presence of four cis-elements, two SMAD-binding elements
and two 12-O-tetradecanoylphorbol-13-acetate–response ele-
ments symmetrically located in both sense and antisense
strands, and minimal overlap in the linker (Supplementary
Table S1 online). These results demonstrated that AFODN4
potently and selectively inhibits AP-1- and SMAD-mediated
transcription. AFODN4 was therefore selected and further
characterized.
The effect of AFODN4 on cell proliferation and apoptosis in
L929 fibroblasts
The treatment of AP-1 decoy ODNs inhibited cardiac fibro-
blast proliferation and matrix metalloproteinase synthesis (Xie
et al., 2009). We therefore investigated the effects of AFODN4
on the proliferation of L929 murine fibroblasts. AFODN4 and
control ONDs efficiently entered the cells (Supplementary
Figure S1 online). We demonstrated that AFODN4 signifi-
cantly inhibited L929 cell proliferation induced by TGF-b1/
TGF-b2 by 40–50% in both our direct cell counting (for
TGF-b1, Scramble decoy vs. AP-1 decoy vs. SMAD decoy
vs. AFODN4: 42.3±6.3 vs. 32.9±5.3 vs. 33.3±5.6
vs. 24.2±3.7; for TGF-b2, Scramble decoy vs. AP-1 decoy
vs. SMAD decoy vs. AFODN4: 45.3±8.6 vs. 35.8±3.8 vs.
34.4±6.4 vs. 25.6±4.5) and our [3H]-thymidine incorpora-
tion assay (for TGF-b1, Scramble decoy vs. AP-1 decoy vs.
SMAD decoy vs. AFODN4:100±8.3 vs. 54.9±5.3
vs. 62.4±5.6 vs. 43.2±5.7; for TGF-b2, Scramble decoy vs.
AP-1 decoy vs. SMAD decoy vs. AFODN4: 100±9.6 vs.
56.8±6.8 vs. 66.4±7.4 vs. 46.9±6.5; Figure 3a and b).
AP-1 or SMAD decoy dsODN was less effective. AFODN4 did
not induce significant apoptosis when used at its therapeutic
concentration (100 nM) in L929 cells (Figure 3c).
The effect of AFODN4 on the production of fibrotic and
inflammatory mediators in L929 cells
We determined the potential antifibrosis activity of AFODN4
in TGF-b1-activated L929 cells. Using quantitative real-time
reverse-transcriptase–PCR (Figure 4a) and western blotting
(Figure 4b and c), we showed that AFODNAFODN4, but
not scramble dsODN, significantly inhibited the mRNA
(Scramble vs. AFODN4) and protein expression of fibrotic
mediators, including PAI-1 (1.84±0.113 vs. 0.71±0.065),
connective-tissue growth factor (2.12±0.211 vs. 0.89±
0.092), fibronectin (2.01±0.126 vs. 0.78±0.091), TGF-b1
(1.99±0.171 vs. 0.85±0.108), Col1a2 (1.50±0.142 vs.
0.83±0.084), and a subunit of the AP-1 complex (c-fos)
(1.77±0.133 vs. 0.94±0.113). AP-1 or SMAD decoy dsODN
was less effective than FODN4 (Figure 4a and b).
Furthermore, SMAD decoy dsODN treatment increased
mRNA (Scramble vs. SMAD vs. AP-1 vs. AFODN4) and
protein expression of several proinflammatory cytokines, such
as IL-6 (0.56±0.054 vs. 0.92±0.099 vs. 0.35±0.037 vs.
0.60±0.086), IL-1b (0.65±0.064 vs. 1.07±0.086 vs. 0.43±
0.054 vs. 0.60±0.043), and tumor necrosis factor-a (TNF-a;
0.64±0.076 vs. 0.96±0.094 vs. 0.37±0.046 vs. 0.64±
0.045) in L929 cells in response to TGF-b1 (Figure 4a–c). In
contrast, AFODN4 and AP-1 decoy dsODNs suppressed their
expression (Figure 4a–c).
AFODN4 inhibits fibrosis and scarring of acute dermal
wounds in mice
On the basis of the antifibrotic and inflammatory properties of
AFODN4 in L929 cells, we next sought to determine the
potential antifibrosis activities of AFODN4 in an acute dermal
wounding mouse model. Local administration of AFODN4,
AP-1 decoy, or SMAD decoy dsODN, but not of scramble
dsODN, suppressed the production of collagen (for hydro-
xyproline content, Scramble vs. AP-1 vs. SMAD vs. AFODN4,
56.8±4.46 vs. 45.3±6.33 vs. 37.9±4.55 vs. 32.1±4.24) in
granulation tissues (Figure 5a, c and d), and reduced the
number of activated fibroblasts or myofibroblasts marked by
Table 1. Dissociation equilibrium constant (KD) of decoy dsODNs binding to AP-1 or SMAD analyzed by SPR
c-Jun SMAD3
No. Kdiss (M
 1 s1) Kass (s
1) Kd (mol l
 1) r Kdiss (M
1 s 1) Kass (s
1) Kd (mol l
1) r
AFODN1 65,976±768 0.00256±0.00013 3.88 108 0.9987 58,967±586 0.00367±0.00021 6.22108 0.9988
AFODN2 14,672±572 0.00568±0.00024 3.87 107 0.9992 8,676±568 0.00669±0.00034 7.71107 0.999
AFODN3 9,674±502 0.00481±0.00021 4.97 107 0.9976 6,627±432 0.00589±0.00036 8.89107 0.9979
AFODN4 84,648±896 0.00228±0.00016 2.70 108 0.9981 74,528±769 0.00339±0.00022 4.54108 0.9983
AP-1 dsODN 96,841±916 0.00204±0.00018 2.11 108 0.9984 — — — —
SMAD dsODN — — — — 94,821±861 0.00309±0.00025 3.26108 0.9987
Abbreviations: AFODN, antifibrosis oligodeoxynucleotide; AP-1, transcription activator protein 1; dsODN, double-stranded oligodeoxynucleotide; SMAD,
small mothers against decapentaplegic; SPR, surface plasmon resonance.
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a-smooth muscle actin (Scramble vs. AP-1 vs. SMAD vs.
AFODN4, 254.4±52.6 vs. 162.6±24.2 vs. 125.8±16.2 vs.
105.4±14.8; Figure 5b and e).
Consistent with our in vitro data, local administration of
AFODN4, AP-1 decoy, or SMAD decoy dsODN significantly
inhibited the expression of fibrotic mediators TGF-b1, con-
nective-tissue growth factor, and PAI-1 (Figure 5f). Interest-
ingly, both AFODN4 and AP-1 decoy dsODN decreased the
expression of inflammatory cytokines IL-1b, IL-6, and TNF-a
in granulation tissues, whereas SMAD decoy dsODN signifi-
cantly increased their expression (Figure 5f). We also con-
firmed that AFODN4 significantly inhibited the DNA-binding
activities of both AP-1 and SMAD in granulation tissues by
electrophoretic mobility shift assay (Figure 5g). These results
demonstrated that AFODN4 suppresses tissue scarring and the
production of fibrotic and inflammatory mediators in mice.
DISCUSSION
Tissue fibrosis and scarring is characterized by overprolifera-
tion of fibroblasts and overproduction of extracellular matrix
components (Pohlers et al., 2009). Abnormal TGF-b signaling
is implicated in a growing number of fibrotic and
inflammatory pathologies (Gordon and Blobe, 2008; Varga
and Pasche, 2008; Pohlers et al., 2009). Therefore, TGF-b
signaling has been considered as a potential therapeutic target
for the treatment of fibrotic diseases (Bonafoux and Lee, 2009;
Hayashida, 2010; Santibanez et al., 2011). AP-1 and SMAD
are two key downstream effectors in the propagation of TGF-b
signaling. AP-1 and SMAD pathways share many overlapping
downstream targets, exhibit cross-talk, and utilize positive and
negative feedback to regulate fibrogenesis (Eickelberg, 2001;
Piek et al., 2001). AP-1 decoy ODN treatment inhibited
cardiac fibroblast proliferation and matrix metalloproteinase
synthesis (Xie et al., 2009). Treatment of single-stranded TGF-b
decoy ODN decreased sponge-induced granuloma growth
and collagen synthesis (Cutroneo and Chiu, 2000). Our results
demonstrated that both TGF-b1 and TGF-b2 promote
the proliferation of L929 cells and activate AP-1- and
SMAD-dependent signaling. Blocking either AP-1 or SMAD
transcriptional programs via selective or dual decoy ODNs
inhibits the proliferation and activation of fibroblasts, as well
as the production of fibrotic mediators.
Three strategies have been developed to inhibit TGF-b
signaling, including antisense nucleotides, mAbs to TGF-bs,
and small-molecule inhibitors of the TGF-b receptor
(Bonafoux and Lee, 2009). It is important to note that there
are three TGF-b ligand isoforms and three receptors, and
that TGF-bs regulate the expression of multiple genes
related to fibrosis via both SMAD-dependent and AP-1- or
mitogen-activated protein kinase–dependent pathways
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(Meyer et al., 2011). It appears difficult to adequately block
TGF-b signaling by targeting a single ligand or receptor. Thus
far, mAbs targeting TGF-b only yielded disappointing results in
several small clinical trials (Varga and Pasche, 2008).
Therefore, simultaneous inhibition of AP-1- and SMAD-
mediated transcription may be a promising strategy to block
TGF-b signal transduction. Decoy ODNs based on cis-
elements provide a more precise and powerful therapeutic
strategy to inhibit transcription factors (Nakagami et al., 2006;
Cutroneo, 2007; Egashira et al., 2008; Zhang et al., 2010).
Our results showed that AFODN4 indeed specifically binds to
both AP-1 and SMAD to inhibit their DNA-binding and
transcriptional activities, and significantly blocks TGF-b-
mediated production of fibrotic mediators in vitro and in vivo.
The inflammatory response is commonly associated with
delayed wound healing and scarring (Leandro et al., 2006;
Sivakumar and Das, 2008). TGF-b plays a complex role in
this process—the SMAD pathway appears to be essential
to suppress inflammation (Walia et al., 2003; Anthoni
et al., 2008), whereas the AP-1 pathway can activate
inflammation (Schonthaler et al., 2011). Our results confirmed
that SMAD decoy ODN alone increases the expression
of proinflammatory cytokines, whereas AP-1 decoy ODN
significantly inhibits their expression. Interestingly, AFODN4
suppressed the production of fibrotic mediators without a
significant increase in the production of proinflammatory
mediators in response to TGF-b. Ablation of the TGF-b
pathway led to delayed wound healing (Crowe et al., 2000),
whereas its proper inhibition accelerated wound healing and
reduced scarring (Huang et al., 2002). Our results confirmed
that AFODN4 at therapeutic concentration did not induce cell
apoptosis. However, the potential toxicity of AFODN4 needs
to be comprehensively evaluated in the future before clinical
applications.
In summary, our study suggests that dual inhibition of
AP-1- and SMAD-dependent pathways might be a useful
strategy for the development of new antifibrosis agents, and
supports further development of AFODN4. This approach
might help control inflammation caused by inhibition of
SMAD-mediated signaling alone.
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Figure 5. Effect of antifibrosis oligodeoxynucleotide 4 (AFODN4) on tissue fibrosis in wounded mice. (a) Granulation tissues were stained for fibrosis using
Masson’s trichrome stain. (b) Immunohistochemistry (IHC) of for a-smooth muscle actin (a-SMA) in the granulation tissues. The positive staining (yellow)
demonstrates a-SMA-positive myofibroblasts. Scale bar¼ 100mm; original magnification 40. (c) Interstitial collagen index assessed by the point-counting
method in Masson’s trichrome–stained sections. (d) Hydroxyproline (HP) contents of the wound bed. (e) The number of myofibroblasts (a-SMA-positive cell)
per field in the wounds. (f) The expression of indicated fibrotic mediators and proinflammatory cytokines in granulation tissues was detected using immuno-blotting
(IB) analysis. (g) DNA binding of transcription activator protein 1 (AP-1) and SMAD (small mothers against decapentaplegic) in granulation tissues was detected
using electrophoretic mobility shift assay (EMSA). *Po0.05, **Po0.01 versus scramble double-stranded oligodeoxynucleotide (dsODN) group.
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MATERIALS AND METHODS
Cell lines, chemicals, and materials
Mouse fibroblast L929 cells and NIH3T3 cells (ATCC, Manassas, VA)
were cultured in DMEM (Cellgro, Herndon, VA) supplemented with
10% (vol/vol) fetal bovine serum (Hyclone, Logan, UT), 100 U ml 1
penicillin, and 100mg ml 1 streptomycin in a humidified atmosphere
with 5% CO2 at 37 1C. Details on human recombinant TGF-b1 and
TGF-b2, various antibodies, chemicals, and preparation of NIH3T3
nuclear extract are found in Supplementary Materials and Methods
online.
Design and synthesis of dual-functional SMAD and AP-1
decoy dsODNs
All decoy and control ODNs including phosphorothioated backbones
or FAM label or biotin labels used in this study were synthesized by
Sangon Biotech Company (Shanghai, People’s Republic of China).
The details of the sequences are found in Supplementary Table S1 of
Supplementary Materials and Methods online. The dsODNs were
created by annealing equal amounts of sense and antisense strands
in phosphate-buffered saline.
Cell proliferation and apoptosis assays
Cell proliferation was assessed by cell counting and [3H]-thymidine
incorporation assay. Apoptosis was analyzed by flow cytometry as
previously described (Wang et al., 2011). Details are found
in Supplementary Materials and Methods online.
Supershift electrophoretic mobility shift assay
The AP-1 probe (5’-ATTTGGAGCGTGTGACTCAGGAGT-30) and a SM
AD probe (5’-TCGAGAGCCAGACAAAAAGCCAGACATTTAGCCAGA
CAC-30) were used with NIH3T3 nuclear extracts and AP-1- or SMAD-
3-specific antibodies as previously described (Wang et al., 2011).
Details are found in Supplementary Materials and Methods online.
Surface plasmon resonance spectroscopy
The measurements were recorded using a BIAcore 3000 instrument
(Biacore, Piscataway, NJ) according to the manufacturer’s instructions
and as previously described (Wang et al., 2011). Details are found in
Supplementary Materials and Methods online.
Luciferase reporter assays
AP-1-responsive, SMAD-responsive, NF-kB-responsive, and STAT1/3-
responsive firefly luciferase plasmids (SA Biosciences, Frederick, MD)
were cotransfected with decoy dsODNs or controls for 12 hours,
followed by the treatment of cytokines (TGF-b for AP-1 and SMAD,
TNF-a for NF-kB, and IFN-g for STAT1/3) for another 24 hours.
Luciferase activity was measured using a luminometer (Promega,
Madison, WI). Results represent the average obtained from at least
three separate experiments. Details are found in Supplementary
Materials and Methods online.
Western blot analysis
Whole-cell lysates from cells or from granulation tissues were prepared
and used for western blot analysis as previously described (Wang et al.,
2011). The primary antibodies used include anti-Fn (dilution, 1:1,000),
anti-IL-6 (1:500), anti-TGF-b1 (1:1,000), anti-PAI-1 (1:500), anti-c-fos
(1:500), anti-Col1a2 (1:1,500), anti-IL-1b (1:1,500), anti-TNF-a
(1:2,000), and anti-b-actin (1:2,000). Details of the antibodies are
found in Supplementary Materials and Methods online.
RNA isolation, synthesis of complementary DNA, and
quantitative real-time reverse-transcriptase–PCR
RNA was extracted from cultured cells or tissues using the RNeasy
Mini Kit (Qiagen, Hombrechtikon, Switzerland) and treated with
DNase I (Promega). Complementary DNA was produced using
the GeneAmp RNA PCR kit (Applied Biosystems, Rotkreuz,
Switzerland). Quantitative PCR analysis was performed with the
Power SYBR Green PCR Master mix (Applied Biosystems) using
gene-specific primers (QuantiTect Primer, Qiagen) with b-actin as
control. Results represent the average obtained from at least five
separate experiments.
Acute dermal wound repair model in mice and immunostaining
Animal studies were performed using 6-week-old male BALB/C mice
(21–23 g) provided by the Animal Breeding Center of Third Military
Medical University (Chongqing, People’s Republic of China). Animals
were individually housed in plastic cages at 20±21C with access to
food and water ad libitum. Animals were kept on a 12-hour light/dark
cycle. Animal experiments were conducted in accordance with the
guidelines of the National Institutes of Health and Third Military
Medical University for laboratory animal care. In brief, mice were
treated with ONDs daily from day 3 to day 6 after wounding and
killed on day 10. The wound specimen and the surrounding 3–4-mm
marginal nonwounded skin was collected for biochemical and histo-
logical analyses. Hydroxyproline levels were used to measure the
amount of collagen in the wound tissues. Details of the procedures
are found in Supplementary Materials and Methods online (Galiano
et al., 2004; Nanney et al., 2000).
Statistical analysis
Results were expressed as means±SEM. The inhibitory effect of
AFODN and scramble decoy dsODN was compared using a two-
tailed Student’s t-test. Differences between multiple groups were
evaluated using one-way analysis of variance, followed by Dunnett’s
post hoc or Tukey’s comparisons. Results were considered statistically
significant at Po0.05.
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